Harshit Jain, MD, is Founder & Global CEO of Doceree.
A pharmaceutical brand will spend years and enormous sums establishing a medicine. Clinical evidence, physician education, patient support, the full apparatus of a modern launch. All of it converges on the single event of a physician deciding to write the prescription.
And then, at the moment that work should matter most, the brand goes dark.
The prescription travels to a pharmacy. Someone the brand has had no way to reach reads it, checks the coverage, weighs the cost and the patient leaves with the medicine that was prescribed—or with something else entirely. That decision, made in seconds at a counter, can undo the entire case the brand spent years building, and the brand is not present for any of it.
This is the blind spot at the center of pharmaceutical marketing, and it has been there so long the industry has stopped seeing it as a gap at all. In my years moving between the exam room and the marketing table, I have watched the commercial machine instrument itself right up to the prescription and go blind the moment after.
Teams measure prescriptions written with real rigor and almost never measure prescriptions filled, even though a pharmacist, a benefits system and a patient’s own hesitation still stand between the two. We have simply accepted that influence ends when the prescription is written.
It does not. A prescription is an intention. Whether it becomes therapy depends largely on what happens next, at the pharmacy.
Why The Counter Went Dark
The scale here is not abstract. A study of nearly 200,000 e-prescriptions from Brigham and Women’s and Massachusetts General Hospital, published in the Journal of General Internal Medicine, found that 28% of new-medication prescriptions were never filled. Cost sharpens that further. A study in the Journal of Clinical Oncology found abandonment of newly prescribed cancer therapies climbing from roughly 10% at low out-of-pocket cost to nearly half above $2,000.
Both failures land after the exam room, in the gap between a written prescription and a filled one. The abandonment figure points more precisely still: it counts patients who reached the counter, met the price and walked away without the drug. That is a decision made at the pharmacy, not in the exam room, and cost alone moves it by tens of points.
The reason is not indifference; no brand team believes the pharmacy is unimportant. The reason is structural. Pharmaceutical media grew up around the moments that could be accessed, including the physician in the exam room and the patient in the waiting room. The pharmacy counter sits inside a workflow that was never built for marketing and was never available as media, so it was left out by default.
The consequence is a strange asymmetry. The moment closest to whether a patient actually starts therapy has had the least brand presence. What I have consistently seen is a marketing budget that shrinks as a prescription gets closer to becoming medicine, the opposite of where the risk of losing the patient is highest.
This is not to say the pharmacy has been ignored. Manufacturers reach patients at the shelf; access and adherence messages move through pharmacy systems. What none of that touches is the pharmacist, inside their own workflow, at the moment a substitution is made or not.
That gap has at least four pressure points: access, affordability, coverage and substitution. Coverage and access are largely negotiated upstream, between payers and manufacturers, hardest for a brand to influence in the moment. Affordability and substitution are different, both decided at the counter itself, which makes them the two points where timely information can still change the outcome.
What Closing The Gap Would Change
Consider what a brand loses in that gap. Not awareness, not preference—those were established upstream. What is lost is the outcome itself, the translation of a decision already made into a medicine the patient actually takes home.
A substitution at the counter is not a failure of persuasion. The persuasion worked; the physician wrote the script. It is a failure of presence. The brand won the argument and then left the room before the argument was settled.
None of this argues that brands should crowd into the pharmacy, or that a pharmacist’s clinical judgment should be anything other than the pharmacist’s own. It argues that being absent from one of the most decisive moments in a prescription’s life has been a strategic error the industry made because it had no alternative.
From Blind Spot To Strategic Opportunity
Before pursuing pharmacy-stage engagement, a brand should weigh its own exposure, including how cost-sensitive its patients are, how often its category faces substitution and what pharmacy presence it already has to build from.
Where that exposure is real, a fix would need to be tied to the specific prescription in front of the pharmacist, not a generic message about the drug class. It would need to reach the pharmacist’s own workflow, not just the patient at the register, and it would need to arrive as part of the same continuous story that began upstream, not a disconnected tactic bolted onto an existing plan. A counter reached in isolation is just one more disconnected placement, and the disconnection was always the real problem.
That is the shift worth watching for—not simply reaching the pharmacy but reaching it as the last moment of one continuous event, tied to the signal that began the encounter. When that becomes possible, the counter stops being the place a prescription goes to be lost and becomes the place a brand finally sees its own work through to the end.
The Bottom Line
The blind spot was never a matter of will. It was a matter of reach and of connection. Both are catching up.
Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?